Fig. 4

Safety findings related to neurotoxicity (safety analysis set). a, Individual serum and CSF levels of NfL over time. The upper limit for the range of the serum NfL assay is 500 pg ml⁻¹. Values above 500 mg ml⁻¹ are imputed to 501 pg ml⁻¹ for the purpose of analysis. Assessment is defined as ‘on treatment’ if the assessment date is within 2 weeks after the last dose. b, Neuropathy-related findings and resolution. A neurological examination finding is defined by two or more consecutive decreased or absent deep tendon reflexes and/or sensory findings. AEs (preferred terms) indicative of neurotoxicity or peripheral neuropathy included axonal and demyelinating polyneuropathy, axonal neuropathy, coordination abnormal, electric shock sensation, hypogeusia, hyporeflexia, loss of proprioception, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy, polyneuropathy and oral discomfort (Supplementary Table 6).